Cellular Therapy Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma
Nausheen Ahmed, A. Ali, Soyoung Kim et al.
· 0 citations
We have 4 of 204 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Sep 2026
Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.
Relapsed or refractory lymphoma carries poor prognosis, with limited options after standard therapies. Spleen tyrosine kinase (SYK) mediates B-cell receptor and aberrant T-cell receptor signaling, promoting survival and proliferation. HMPL-523 (sovleplenib) is a novel, selective oral SYK inhibitor with preclinical acti...
P. Strati, D. Chraniuk, E. González Barca et al.
· Blood Advances · 0 citations
Open access
Aug 2026
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma.
This study demonstrated superior response rate and PFS of CD19 CAR-T over platinum-based salvage with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
Xi Yang, Henry Dumke, Swetha Kambhampati Thiruvengadam et al.
· Blood Advances · 0 citations
Review
Open access
Jul 2026
Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee
Recommendations developed provide a sound basis for practical counseling and decision-making in the care of patients with treatment-naïve and relapsed/refractory MCL.
P. Dreger, G. Iacoboni, S. Robinson et al.
· Bone Marrow Transplantation · 0 citations